Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Eligible age
18–99 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
Sponsor: Massachusetts General Hospital
You may qualify if…
- ✓ Liver cirrhosis as diagnosed by imaging and/or clinical data, including pathology
You may not qualify if…
- ✕ Any contraindication to PET, as in attached screening form
- ✕ Any contraindication to MRI, as in attached screening form
- ✕ Any contraindication to gadolinium-based contrast agent, including allergy to gadolinium, as in attached screening forms.
- ✕ Pregnancy
- ✕ Breast feeding.
- ✕ Cumulative radiation exposure for research studies during the prior 12 months, combined with the exposure from this study, \> 50 mSv
- ✕ Inability to fit in the scanner: weight \> 300 lbs or BMI \> 33
Where it's recruiting
Charlestown
Source: ClinicalTrials.gov · NCT06265272 · last updated 2025-09-26